OncoZenge Past Earnings Performance
Past criteria checks 0/6
OncoZenge's earnings have been declining at an average annual rate of -13%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 163.8% per year.
Key information
-13.0%
Earnings growth rate
65.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | 163.8% |
| Return on equity | -85.3% |
| Net Margin | -530,066.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How OncoZenge makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -16 | 16 | 0 |
| 30 Sep 23 | 0 | -17 | 7 | 10 |
| 30 Jun 23 | 0 | -16 | 6 | 11 |
| 31 Mar 23 | 0 | -15 | 6 | 9 |
| 31 Dec 22 | 0 | -47 | 6 | 38 |
| 30 Sep 22 | 0 | -43 | 6 | 35 |
| 30 Jun 22 | 0 | -41 | 5 | 33 |
| 31 Mar 22 | 0 | -39 | 5 | 32 |
| 31 Dec 21 | 0 | -4 | 5 | 0 |
Quality Earnings: ONCOZ is currently unprofitable.
Growing Profit Margin: ONCOZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ONCOZ's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ONCOZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONCOZ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.8%).
Return on Equity
High ROE: ONCOZ has a negative Return on Equity (-85.31%), as it is currently unprofitable.